Biocompatible nanocarrier fortified with a dipyridinium-based amphiphile for eradication of biofilm

ACS Applied Materials and Interfaces

Volumn 6, Issue 18, 2014, Pages 16384-16394

  Goswami, Sudeep ^a   Thiyagarajan, Durairaj ^a   Das, Gopal ^a   Ramesh, Aiyagari ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

Amphiphile; Antibacterial; Antibiofilm; Antibiotic; Catheter; HSA nanocarrier

Indexed keywords

AMPHIPHILES; ANTIBIOTICS; BACTERIA; BIOCOMPATIBILITY; CATHETERS; CELL CULTURE; PH;

ANTAGONISTIC EFFECTS; ANTI-BIOFILM; ANTIBACTERIAL; CATIONIC AMPHIPHILE; HUMAN SERUM ALBUMINS; MICROSCOPIC ANALYSIS; NANOCARRIERS; PSEUDOMONAS AERUGINOSA;

BIOFILMS;

ANTIINFECTIVE AGENT; BIOMATERIAL; DRUG CARRIER; NANOMATERIAL; PYRIDINIUM DERIVATIVE; SERUM ALBUMIN;

BACTERIUM; BIOFILM; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HELA CELL LINE; HUMAN;

ANTI-BACTERIAL AGENTS; BACTERIA; BIOCOMPATIBLE MATERIALS; BIOFILMS; CELL SURVIVAL; DRUG CARRIERS; HELA CELLS; HUMANS; NANOSTRUCTURES; PYRIDINIUM COMPOUNDS; SERUM ALBUMIN;

EID: 84912040805     PISSN: 19448244     EISSN: 19448252     Source Type: Journal    
DOI: 10.1021/am504779t     Document Type: Article

References (58)

1. Costerton, J. W.; Stewart, P. S.; Greenberg, E. P. Bacterial Biofilms: A Common Cause of Persistent Infections. Science 1999, 284, 1318-1322.
2. Archer, N. K.; Mazaitis, M. J.; Costerton, W.; Leid, J. G.; Powers, M. E.; Shirtliff, M. E. Staphylococcus aureus Biofilms: Properties, Regulation and Roles in Human Disease. Virulence 2011, 2, 445-459.
3. Flemming, H. C.; Wingender, J. The Biofilm Matrix. Nat. Rev. Microbiol. 2010, 8, 623-633.
4. Kostakioti, M.; Hadjifrangiskou, M.; Hultgren, S. J. Bacterial Biofilms: Development, Dispersal, and Therapeutic Strategies in the Dawn of the Postantibiotic Era. Cold Spring Harb. Perspect. Med. 2013, 3, a010306.
5. Donlan, R. M.; Costerton, J. W. Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms. Clin. Microbiol. Rev. 2002, 15, 167-193.
6. Bordi, C.; Bentzmann, S. D. Hacking into Bacterial Biofilms: A New Therapeutic Challenge. Ann. Intensive Care 2011, 1, 19.
7. Otto, M. Staphylococcal Biofilms. Curr. Top. Microbiol. Immunol. 2008, 322, 207-228.
8. Mann, E. E.; Wozniak, D. J. Pseudomonas Biofilm Matrix Composition and Niche Biology. FEMS Microbiol. Rev. 2012, 36, 893-916.
9. Parsek, M. R.; Singh, P. K. Bacterial Biofilms: An Emerging Link to Disease Pathogenesis. Annu. Rev. Microbiol. 2003, 57, 677-701.
10. Davies, D. Understanding Biofilm Resistance to Antibacterial Agents. Nat. Rev. Drug Discovery 2003, 2, 114-122.
11. Wagner, V. E.; Iglewski, B. H. P. aeruginosa Biofilms in CF Infection. Clin. Rev. Allergy Immunol. 2008, 35, 124-134.
12. Gomez, M. I.; Prince, A. Opportunistic Infections in Lung Disease: Pseudomonas Infections in Cystic Fibrosis. Curr. Opin. Pharmacol. 2007, 7, 244-251.
13. Arciola, C. R.; Campoccia, D.; Speziale, P.; Montanaro, L.; Costerton, J. W. Biofilm Formation in Staphylococcus Implant Infections. A Review of Molecular Mechanisms and Implications for Biofilm-Resistant Materials. Biomaterials 2012, 33, 5967-5982.
14. Trautner, B. W.; Darouiche, R. O. Catheter-Associated Infections: Pathogenesis Affects Prevention. Arch. Int. Med. 2004, 164, 842-850.
15. Warren, J. W. Catheter-Associated Urinary Tract Infections. Int. J. Antimicrob. Agents 2001, 17, 299-303.
16. Hoiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic Resistance of Bacterial Biofilms. Int. J. Antimicrob. Agents 2010, 35, 322-332.
17. Stewart, P. S.; Costerton, J. W. Antibiotic Resistance of Bacteria in Biofilms. Lancet 2001, 358, 135-138.
18. Fux, C. A.; Costerton, J. W.; Stewart, P. S.; Stoodley, P. Survival Strategies of Infectious Biofilms. Trends Microbiol. 2005, 13, 34-40.
19. Broderick, A. H.; Breitbach, A. S.; Frei, R.; Blackwell, H. E.; Lynn, D. M. Surface-Mediated Release of a Small-Molecule Modulator of Bacterial Biofilm Formation: A Non-Bactericidal Approach to Inhibiting Biofilm Formation in Pseudomonas aeruginosa. Adv. Healthcare Mater. 2013, 2, 993-1000.
20. Bunders, C.; Cavanagh, J.; Melander, C. Flustramine Inspired Synthesis and Biological Evaluation of Pyrroloindoline Triazole Amides as Novel Inhibitors of Bacterial Biofilms. Org. Biomol. Chem. 2011, 9, 5476-5481.
21. Geske, G. D.; Wezeman, R. J.; Siegel, A. P.; Blackwell, H. E. Small Molecule Inhibitors of Bacterial Quorum Sensing and Biofilm Formation. J. Am. Chem. Soc. 2005, 127, 12762-12763.
22. Worthington, R. J.; Richards, J. J.; Melander, C. Small Molecule Control of Bacterial Biofilms. Org. Biomol. Chem. 2012, 10, 7457-7474.
23. Singh, V.; Arora, V.; Alam, J. M.; Garey, K. W. Inhibition of Biofilm Formation by Esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob. Agents Chemother. 2012, 56, 4360-4364.
24. Vudumula, U.; Adhikari, M. D.; Ojha, B.; Goswami, S.; Das, G.; Ramesh, A. Tuning the Bactericidal Repertoire and Potency of Quinoline-based Amphiphiles for Enhanced Killing of Pathogenic Bacteria. RSC Adv. 2012, 2, 3864-3871.
25. Goswami, S.; Adhikari, M. D.; Kar, C.; Thiyagarajan, D.; Das, G.; Ramesh, A. Synthetic Amphiphiles as Therapeutic Antibacterials: Lessons on Bactericidal Efficacy and Cytotoxicity and Potential Application as an Adjuvant in Antimicrobial Chemotherapy. J. Mater. Chem. B 2013, 1, 2612-2623.
26. Thiyagarajan, D.; Goswami, S.; Kar, C.; Das, G.; Ramesh, A. A Prospective Antibacterial for Drug-Resistant Pathogens: A Dual Warhead Amphiphile Designed to Track Interactions and Kill Pathogenic Bacteria by Membrane Damage and Cellular DNA Cleavage. Chem. Commun. 2014, 50, 7434-7436.
27. Zhang, L.; Pornpattananangkul, D.; Hu, C. M.; Huang, C. M. Development of Nanoparticles for Antimicrobial Drug Delivery. Curr. Med. Chem. 2010, 17, 585-594.
28. Risbud, M. V.; Hardikar, A. A.; Bhat, S. V.; Bhonde, R. R. pHSensitive Freeze-Dried Chitosan-Polyvinyl Pyrrolidone Hydrogels as Controlled Release System for Antibiotic Delivery. J. Controlled Release 2000, 68, 23-30.
29. Alphandary, H. P.; Andremont, A.; Couvreur, P. Targeted Delivery of Antibiotics Using Liposomes and Nanoparticles: Research and Applications. Int. J. Antimicrob. Agents 2000, 13, 155-168.
30. Applerot, G.; Lellouche, J.; Perkas, Nina.; Nitzan, Y.; Gedanken, A.; Banin, E. ZnO Nanoparticle-Coated Surfaces Inhibit Bacterial Biofilm Formation and Increase Antibiotic Susceptibility. RSC Adv. 2012, 2, 2314-2321.
31. Adhikari, M. D.; Goswami, S.; Panda, B. R.; Chattopadhyay, A.; Ramesh, A. Membrane-Directed High Bactericidal Activity of (Gold Nanoparticle)-Polythiophene Composite for Niche Applications Against Pathogenic Bacteria. Adv. Healthcare Mater. 2013, 2, 599-606.
32. Slomberg, D. L.; Lu, Y.; BroaDNAx, A. D.; Hunter, R. A.; Carpenter, A. W.; Schoenfisch, M. H. Role of Size and Shape on Biofilm Eradication for Nitric Oxide-Releasing Silica Nanoparticles. ACS Appl. Mater. Interfaces 2013, 5, 9322-9329.
33. Shimanovich, U.; Bernardes, G. J. L.; Knowles, T. P. J.; Cavaco-Paulo, A. Protein Micro-And Nano-Capsules for Biomedical Applications. Chem. Soc. Rev. 2014, 43, 1361-1371.
34. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. Protein-Based Nanocarriers as Promising Drug and Gene Delivery Systems. J. Controlled Release 2012, 161, 38-49.
35. Kratz, F. Albumin as a Drug Carrier: Design of Prodrugs, Drug Conjugates and Nanoparticles. J. Controlled Release 2008, 132, 171-183.
36. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. Albumin-based Nanoparticles as Potential Controlled Release Drug Delivery Systems. J. Controlled Release 2012, 157, 168-182.
37. Lambert, P. A. Mechanisms of Antibiotic Resistance in Pseudomonas aeruginosa. J. R. Soc. Med. 2002, 95 (Suppl. 41), 22-26.
38. Stewart, P. S. Mechanisms of Antibiotic Resistance in Bacterial Biofilms. Int. J. Med. Microbiol. 2002, 292, 107-113.
39. Hogan, D.; Kolter, R. Why are Bacteria Refractory to Antimicrobialš Curr. Opin. Microbiol. 2002, 5, 472-477.
40. Church, D.; Elsayed, S.; Reid, O.; Winston, B.; Lindsay, R. Burn Wound Infections. Clin. Microbiol. Rev. 2006, 19, 403-434.
41. Anderson, G. G.; Moreau-Marquis, S.; Stanton, B. A.; O'Toole, G. A. In Vitro Analysis of Tobramycin-Treated Pseudomonas aeruginosa Biofilms on Cystic Fibrosis-Derived Airway Epithelial Cells. Infect. Immun. 2008, 76, 1423-1433.
42. Tseng, B. S.; Zhang, W.; Harrison, J. J.; Quach, T. P.; Song, J. L.; Penterman, J.; Singh, P. K.; Chopp, D. L.; Packman, A. I.; Parsek, M. R. The Extracellular Matrix Protects Pseudomonas aeruginosa Biofilms by Limiting the Penetration of Tobramycin. Environ. Microbiol. 2013, 15, 2865-2878.
43. Walters, M. C., III; Roe, F.; Bugnicourt, A.; Franklin, M. J.; Stewart, P. S. Contributions of Antibiotic Penetration, Oxygen Limitation, and Low Metabolic Activity to Tolerance of Pseudomonas aeruginosa Biofilms to Ciprofloxacin and Tobramycin. Antimicrob. Agents Chemother. 2003, 47, 317-323.
44. Olson, K. M.; Starks, C. M.; Williams, R. B.; O'Neil-Johnson, M.; Huang, Z.; Ellis, M.; Reilly, J. E.; Eldridge, G. R. Novel Pentadecenyl Tetrazole Enhances Susceptibility of Methicillin-Resistant Staphylococcus aureus Biofilms to Gentamicin. Antimicrob. Agents Chemother. 2011, 55, 3691-3695.
45. Rogers, A.; Huigens, R. W.; Cavanagh, J.; Melander, C. Synergistic Effects Between Conventional Antibiotics and 2-Aminoimidazole-Derived Antibiofilm Agents. Antimicrob. Agents Chemother. 2010, 54, 2112-2118.
46. Kim, J.; Pitts, B.; Stewart, P. S.; Camper, A.; Yoon, J. Comparison of the Antimicrobial Effects of Chlorine, Silver Ion, and Tobramycin on Biofilm. Antimicrob. Agents Chemother. 2008, 52, 1446-1453.
47. Drew, K. R. P.; Sanders, L. K.; Culumber, Z. W.; Zribi, O.; Wong, G. C. L. Cationic Amphiphiles Increase Activity of Aminoglycoside Antibiotic Tobramycin in the Presence of Airway Polyelectrolytes. J. Am. Chem. Soc. 2009, 131, 486-493.
48. Lode, H. Tobramycin: A Review of Therapeutic Uses and Dosing Schedules. Curr. Ther. Res. 1998, 59, 420-453.
49. Langer, K.; Balthasar, S.; Vogel, V.; Dinauer, N.; von Briesen, H.; Schubert, D. Optimization of the Preparation Process for Human Serum Albumin (HSA) Nanoparticles. Int. J. Pharm. 2003, 257, 169-180.
50. Craig, W. A. Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men. Clin. Infect. Dis. 1998, 26, 1-12.
51. Mueller, M.; de la Pena, A.; Derendorf, H. Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC. Antimicrob. Agents Chemother. 2004, 48, 369-377.
52. Wispelwey, B. Clinical Implications of Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. Clin. Infect. Dis. 2005, 41, S127-S135.
53. Craig, W. A. Basic pharmacodynamics of Antibacterials with Clinical Applications to the Use of β-Lactams, Glycopeptides, and Linezolid. Infect. Dis. Clin. North Am. 2003, 17, 479-501.
54. Noimark, S.; Dunnill, C. W.; Wilson, M.; Parkin, I. P. The Role of Surfaces in Catheter-Associated Infections. Chem. Soc. Rev. 2009, 38, 3435-3448.
55. Hetrick, E. M.; Schoenfisch, M. H. Reducing Implant-Related Infections: Active Release Strategies. Chem. Soc. Rev. 2006, 35, 780-789.
56. Gutiérrez-González, R.; Boto, G. R. Do Antibiotic-Impregnated Catheters Prevent Infection in CSF Diversion Procedureš Review of the literature. J. Infect. 2010, 61, 9-20.
57. Furno, F.; Morley, K. S.; Wong, B.; Sharp, B. L.; Arnold, P. L.; Howdle, S. M.; Bayston, R.; Brown, P. D.; Winship, P. D.; Reid, H. J. Silver Nanoparticles and Polymeric Medical Devices: A New Approach to Prevention of Infection? J. Antimicrob. Chemother. 2004, 54, 1019-1024.
58. Muder, R. R.; Brennen, C.; Rihs, J. D.; Wagener, M. M.; Obman, A.; Stout, J. E.; Yu, V. L. Isolation of Staphylococcus aureus from the Urinary Tract: Association of Isolation with Symptomatic Urinary Tract Infection and Subsequent Staphylococcal Bacteremia. Clin. Infect. Dis. 2006, 42, 46-50.